Tobira Therapeutics Inc. Presents Pharmacokinetics and Safety Data that Support Coadministration of Cenicriviroc with Tenofovir DF in Healthy Adults
7/19/2011 9:12:22 AM
MANALAPAN, N.J.--(BUSINESS WIRE)--Tobira Therapeutics, a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV infection, announced the results of a Phase l, open-label, cross-over study that explored the pharmacokinetics (PK), safety and tolerability of cenicriviroc (CVC) and tenofovir disoproxil fumarate (TDF) when coadministered in healthy adults. The study findings were presented today at the 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Rome, Italy.
comments powered by